R. Senevirathna, P.D.C.P. Thalwatta, and

R.A.N. Wickramasinghe for their valuable contributions to implementation of the study. Finally, the authors would like to thank Drs. J. Jacobsen and S. Hills, formerly of PATH, for their contributions to the design and oversight of the study; Dr. N. Kanakaratne of Genetech for management and international shipping of specimens; and M. Issa for statistical analyses. Special thanks go to R. Miranda, Dr. C. Siriwardhana, C. Deano, and S. Umandap of Quintiles, Singapore and A. Ghosh, S. Chakraborty, M. Goswami, A. Das, G. Padashetty, and S. Machado of Quintiles, India for their assistance to the investigators and PATH. At PATH, we also acknowledge the contributions of J. Fleming, GSK1120212 purchase K. Kelly, J. Udd, N. Bhat, and A. Marfin for their technical advice and/or administrative assistance, selleck screening library and G. Topel for her expert contracting and financial oversight. Contributors and role of the funding source: MRNA, PRW, MY, and JCV contributed

to the study design. MRNA and PRW supervised the implementation of the study at the sites. YS supervised the conduct of all laboratory assays. JCV and PRW verified protocol-stated statistical analyses that were conducted by a statistical consultant; JCV conducted post-hoc analyses. All authors had full access to the data and results. MRNA, PRW, KMN, MY, and JCV participated in drafting of this manuscript or in critically revising the draft. All authors reviewed and approved the final version of the manuscript. The corresponding author had final responsibility for the decision to submit for publication. Investigators GBA3 and their institution were funded by PATH’s Japanese Encephalitis Project, under a grant from the Bill and Melinda Gates Foundation. CDIBP donated LJEV vaccine for the study, and their staff approved of the study but held only observer/advisor status. PATH acted as the regulatory sponsor, and PATH and a PATH-designated CRO were responsible for study initiation, clinical monitoring,

pharmacovigilence, data management, data analysis, and reporting. Conflict of interest: Y. Yao, B. Zhou, and L. Zhang are employees of CDIBP. K. Neuzil and J. Victor are employees of PATH, which has received a grant from the Bill and Melinda Gates Foundation to ensure quality, supply, and optimal programmatic use of SA 14-14-2 LJEV in low-resource populations in Asia. No other conflicts of interest were identified. “
“The VERO cell line represents a well-characterized, immortalized line of African green monkey kidney (AGMK) cells that is susceptible to a broad range of viruses [1], [2], [3] and [4]. These cells are used as the cell substrate reagents for the manufacture of several viral vaccines including vaccines against poliomyelitis, rabies, rotavirus, smallpox, and influenza [2], [3], [4], [5], [6], [7] and [8].